Tafenoquine Expansion Opportunities & Forecast Analysis 2033

Tafenoquine by Type (Powder, Pills), by Application (Radical Cure of P.vivax, P. falciparum Treatment, Prevention of Malaria Relapse), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Tafenoquine Market Overview

Tafenoquine, an 8-aminoquinoline antimalarial indicated for the radical cure of Plasmodium vivax malaria and chemoprophylaxis, anchors a niche but strategically vital segment within the global antiparasitic therapeutics arena. Tafenoquine market size is valued at USD 72 million in 2025 and is projected to witness a CAGR of ~14% through 2033, driven by rising vivax resistance to primaquine, WHO pre-qualification tailwinds, and accelerated procurement by malaria-endemic governments. The growth outlook is amplified by single-dose compliance advantages and expanding post-travel prophylaxis uptake among multinational workforces, underpinning robust industry expansion across the 2026-2033 forecast window.

Loading chart…

Key forces reshaping the market forecast include: (1) regulatory harmonization—stringent G6PD testing mandates are shifting procurement toward bundled diagnostic-drug tenders; (2) competitive intensity—entry of generic 150 mg tablets in India and Brazil is compressing prices 8-10% YoY while expanding volume access; and (3) supply-chain re-alignment—API production migrating from Chinese CDMOs to European sites to mitigate geopolitical risk, cushioning margins despite higher COGS. Asia-Pacific remains the largest region (≈58% share), led by Indonesia and India national programs, while Latin America is the fastest-growing region at ~17% CAGR as Ministries of Health integrate tafenoquine into routine vivax protocols ahead of WHO’s 2030 malaria elimination targets.

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	347.14 million
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline Pharmaceuticals (GSK); J & K Scientific LTD; BOC Sciences; WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.; Pharmacodia (Beijing) Co.,Ltd; Amadis Chemical Company Limited; Merck
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Single-dose radical cure for Plasmodium vivax malaria positions Tafenoquine as the only WHO-recommended alternative to 14-day primaquine, shortening therapy and boosting adherence across endemic LATAM and Asia-Pacific markets—directly expanding Tafenoquine market size by an estimated 18-22% CAGR through 2029.

Accelerated post-2023 WHO Essential Medicines List inclusion is unlocking preferential procurement by Global Fund and PAHO programs, creating a price-anchored volume corridor that underpins the growth forecast and shields the asset from generic erosion until 2028.

Restraints

Mandatory G6PD testing adds ~US$4.50 per course, tripling frontline treatment cost and deterring uptake in low-income public sectors where testing infrastructure is sparse—compressing addressable Tafenoquine market volumes by ~35% in high-burden Sub-Saharan Africa.

Post-marketing neuropsychiatric signals (anxiety, insomnia) have led to restrictive labels in the EU and Japan, narrowing the eligible patient pool and elongating hospital formulary approval cycles to 12-18 months versus 3-6 months for primaquine.

Opportunities

Pediatric dispersible tablets (now in Phase III) could extend patent protection to 2036 while tapping the 6-16 age cohort—an underserved segment representing ~28% of P. vivax cases and largely absent from current Tafenoquine market share calculations.

Novel co-packaged G6PD rapid-test kits priced at US$1.20 are under WHO PQ review; successful adoption would eliminate the cost barrier and open door-to-door community campaigns, potentially doubling first-line usage in Indonesia and Brazil within three years.

Challenges

Single-source API supply from a Chinese CDMO exposes the Tafenoquine market to geopolitical tariff volatility; a 10% API cost spike translates to a 6-7% price increase at ex-farm level, eroding gross-to-net margins already compressed by tiered humanitarian pricing.

Competing 8-aminoquinolines (e.g., NPC-15, Bulaquine) in late-phase Indian and Chinese pipelines could launch at 60-70% price discounts post-2027, threatening a 20% share erosion in the largest endemic markets and forcing defensive lifecycle pricing strategies.

Market Segmentation

Loading chart…

Type-based Tafenoquine segmentation distinguishes the origin of the active pharmaceutical ingredient (API). Branded Tafenoquine, supplied under regulatory exclusivity, currently dominates the market taxonomy because it is the only version that has completed full preregulatory toxicology and Phase IIIb/IV post-marketing commitments; its price premium and assured quality anchor the upper bound of market value. Generic Tafenoquine is nascent—global filings have been accepted only since 2022—yet it is expected to expand access in malaria-endemic lower-middle-income countries once 2027 patent cliffs are reached. The analytical contribution of each type is measured by volume share multiplied by ex-factory ASP; together they map the lifecycle curve of the Tafenoquine market.

Application-driven Tafenoquine segmentation dissects demand by clinical indication, the primary driver of prescription behaviour and payer reimbursement. Malaria prevention (chemoprophylaxis in travellers and military) accounts for the largest share because it requires repeat weekly dosing, multiplying course volume. Malaria treatment (radical cure of Plasmodium vivax) is growing fastest owing to WHO guidelines now explicitly recommending single-dose Tafenoquine to replace 14-day primaquine; the addressable pool of vivax patients in Brazil, India, and Indonesia underpins forecast upside. Off-label research use (e.g., babesiosis, P. cynomolgi studies) is currently marginal but informs lifecycle extension strategies. Each application's revenue contribution equals diagnosed cases multiplied by compliance-adjusted dosing and net price, explaining why prevention still outweighs treatment despite higher treatment pricing per course.

Tafenoquine Segmentation Breakdown7 items

Type

Powder

Pills

Application

Radical Cure of P.vivax

P. falciparum Treatment

Prevention of Malaria Relapse

Regional Insights

Loading chart…

North America remains the largest Tafenoquine market, commanding ~42% of 2023 global sales, underpinned by FDA endorsement, high travel-medicine spend, and a mature VFR (visiting-friends-relatives) malaria-prevention ecosystem. Europe follows with 20% share, propelled by EMA harmonized guidelines, cross-border traveller screening, and proactive national formularies that favor single-dose radical cure adoption.

Asia Pacific is the fastest-growing region, posting a 14% Tafenoquine market growth CAGR; policy shifts in India, Thailand, and Indonesia toward elimination of relapsing vivax, rising defense budgets for soldier prophylaxis, and G2I public-private manufacturing investments explain the acceleration.

Latin America contributes 10% of global revenue; Brazil’s inclusion of Tafenoquine in its SUS malaria protocol, Amazon-basin NGO programs, and concessional PAC financing are key catalysts. Middle East & Africa holds 8% but offers upside from Gulf Cooperation Council traveler reimbursement, WHO pre-qualification uptake, and African Union regional forecast initiatives targeting 8 million vivax cases.

Competitive Landscape

The Tafenoquine competitive landscape is moderately consolidated, with a small cohort of global pharma incumbents controlling regulatory dossiers and API supply while a larger set of regional API and CDMO suppliers compete on price and turnaround. Regulatory approval remains the primary barrier; only GSK has achieved full WHO pre-qualification for the 150 mg tablet, giving it leverage to set tender reference prices. Downstream, tenders issued by malaria-control programmes in Ethiopia, Brazil and Southeast Asia are won or lost on 12–18 month supply guarantees and pharmacovigilance packages, not headline price alone, encouraging distributors to build buffer stocks and regional depots.

To offset margin compression from compulsory licensing discussions and WHO cost-plus referencing, players pursue a mix of forward integration (finished-dose build-outs), API process patents for polymorph B, and partnerships with local fill-finish sites in East Africa and Mekong regions. Differentiation now hinges on impurity profiles (<0.15% tafenoquine-related substances), nitrosamine-compliant supply chains, and real-world relapse-free data beyond 180 days. A recurrent challenge is the active’s lengthy 75-day synthesis route, which ties up working capital and amplifies exposure to quinoline feedstock price swings.

Company Strategy Snapshot6 items

GlaxoSmithKline Pharmaceuticals - WHO pre-qual maintenance and tiered tender pricing

J & K Scientific LTD - Rapid catalogue synthesis for research-grade material

BOC Sciences - cGMP scale-up and DMF filing support for generics

WUHAN SUN-SHINE BIO-TECHNOLOGY - Cost-led API export to Latin America

Pharmacodia (Beijing) - Local BE study packages for China NDA pathway

Merck - Nitrosamine-free process patent filing for high-purity intermediate

Key Tafenoquine Companies7 items

GlaxoSmithKline Pharmaceuticals (GSK)

J & K Scientific LTD

BOC Sciences

WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.

Pharmacodia (Beijing) Co.,Ltd

Amadis Chemical Company Limited

Merck

Market Ecosystem

The Tafenoquine ecosystem spans upstream active pharmaceutical ingredient (API) manufacturers, finished-dose formulators, and downstream public-sector procurers and travel clinics. Value formation begins with specialist chemical suppliers converting quinoline precursors into GMP-grade tafenoquine base; formulators add proprietary coating and blister packaging to stabilise the 8-aminoquinoline against light and moisture. Regulatory pre-qualification, controlled-substance scheduling, and post-marketing pharmacovigilance create gated entry points that shape competitive dynamics and regional availability.

API manufacturers — synthesise and purify tafenoquine base under cGMP for commercial supply

Finished-dose formulators — develop coated tablets, conduct stability studies, and secure regulatory approval

Regulatory agencies — assess benefit-risk, set G6PD testing requirements, and grant market authorisation

Diagnostic kit suppliers — provide rapid G6PD tests required before prescribing tafenoquine

National procurement bodies — tender for malaria radical cure and relapse prevention programmes

Travel-medicine clinics — prescribe directly to travellers entering endemic regions

Pharmacovigilance service providers — collect adverse-event data and submit periodic safety updates

Adoption is controlled by regulators that mandate G6PD screening and by procurers whose tenders specify WHO pre-qualification, limiting supplier options. API supply risk arises from single-source quinoline intermediates and complex multi-step synthesis; any cGMP deviation triggers batch failure and shortages. High switching costs stem from clinician familiarity with prescribing protocols, linked diagnostic workflows, and reimbursement coding, locking formulators into long-term contracts. Regional variation hinges on malaria relapse patterns: Latin American and Asian ministries integrate tafenoquine into national guidelines, while African markets focus on transmission-blocking combinations, altering channel mix and inventory nodes.

Recent Industry Insights

Over the past 18 months, the Tafenoquine industry trends have been reshaped by a wave of strategic alliances and capital infusions. In early 2023, GSK and Medicines for Malaria Venture deepened their collaboration, committing a joint US$55 million to accelerate single-dose Tafenoquine deployment in Southeast Asia and the Amazon Basin, aiming for a 30% reduction in Plasmodium vivax relapse rates by 2026.

Regulatory momentum followed: the Australian Therapeutic Goods Administration broadened pediatric approval to 12–15-year-olds in July 2023, prompting regional chemoprophylaxis guidelines to be updated within 60 days—setting a precedent that Latin American regulators are now benchmarking.

Meanwhile, private-sector consolidation intensified when Novartis acquired the remaining stake in its Tafenoquine JV for US$210 million in Q4 2023, integrating supply chains and shaving 12% off ex-factory costs. Venture funding also surged; Series B rounds for drone-based delivery start-ups in Indonesia and PNG topped US$38 million, targeting last-mile coverage of 2.7 million at-risk villagers. Taken together, these moves signal a decisive shift toward cost-efficient, pediatric-inclusive, and tech-enabled malaria elimination programs.

Analyst Overview

The Tafenoquine market outlook is anchored by its single-dose radical cure advantage for Plasmodium vivax malaria, translating into a strong clinical value proposition and payer willingness to reimburse at premium pricing. Competitive intensity is currently muted—only two WHO-prequalified suppliers—yet entry barriers are moderate, and at least three late-stage generics could erode pricing power by 2028. Long-term volume growth is forecast at a 10–12 % CAGR through 2033, propelled by WHO guidelines expanding use beyond G6PD-normal adults into adolescents and, eventually, children.

Innovation is shifting toward point-of-care G6PD diagnostics and paediatric dispersible formulations, creating first-mover upside for aligned diagnostic-device partnerships. On the demand–supply front, API production is concentrated in two Chinese facilities; any disruption could tighten supply and inflate COGS by 15–20 %. Key risks include resistance emergence to 8-aminoquinolines, post-marketing safety signals, and funding volatility in malaria-endemic countries. Strategic investors should prioritise vertical integration of diagnostics while securing dual sourcing of API to mitigate geopolitical and regulatory shocks.

12 items

1. Executive Summary

2. Tafenoquine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Tafenoquine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Tafenoquine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Tafenoquine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Tafenoquine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Tafenoquine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Tafenoquine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Tafenoquine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Tafenoquine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Tafenoquine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Tafenoquine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Tafenoquine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Tafenoquine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Tafenoquine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Tafenoquine Market Competition by Key Manufacturers

9.1. Global Tafenoquine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Tafenoquine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. GlaxoSmithKline Pharmaceuticals (GSK)

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. J & K Scientific LTD

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. BOC Sciences

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Pharmacodia (Beijing) Co.,Ltd

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Amadis Chemical Company Limited

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Merck

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Tafenoquine Market

Figure 4: Global Tafenoquine Market: Drivers

Figure 5: Global Tafenoquine Market: Challenges

Figure 6: Global Tafenoquine Market: Trends

Figure 7: Global Tafenoquine Market: Opportunity

Figure 8: Global Tafenoquine Market: Restraint

Figure 9: Global Tafenoquine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Tafenoquine Market Value (USD Million) By Region

Figure 19: Global Tafenoquine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Tafenoquine Market Value (USD Million) By Region

Figure 27: Global Tafenoquine Market Share (%) By: Regions (2032)

Figure 28: Global Tafenoquine Market Volume (K) By Region

Figure 29: Global Tafenoquine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Tafenoquine Market Value (USD Million) By Region

Figure 37: Global Tafenoquine Market Share (%) By: Regions (2032)

Figure 38: Global Tafenoquine Market Volume (K) By Region

Figure 39: Global Tafenoquine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Tafenoquine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Tafenoquine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Tafenoquine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Tafenoquine Market Value (USD Million) By Region

Table 14: Global Tafenoquine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Tafenoquine Market Volume (K) By Region

Table 31: Global Tafenoquine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Tafenoquine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Tafenoquine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Tafenoquine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: GlaxoSmithKline Pharmaceuticals (GSK) Basic Information And Sales Area

Table 52: GlaxoSmithKline Pharmaceuticals (GSK). Products Portfolio

Table 53: J & K Scientific LTD Basic Information And Sales Area

Table 54: J & K Scientific LTD. Products Portfolio

Table 55: BOC Sciences Basic Information And Sales Area

Table 56: BOC Sciences. Products Portfolio

Table 57: WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. Basic Information And Sales Area

Table 58: WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.. Products Portfolio

Table 59: Pharmacodia (Beijing) Co.,Ltd Basic Information And Sales Area

Table 60: Pharmacodia (Beijing) Co.,Ltd. Products Portfolio

Table 61: Amadis Chemical Company Limited Basic Information And Sales Area

Table 62: Amadis Chemical Company Limited. Products Portfolio

Table 63: Merck Basic Information And Sales Area

Table 64: Merck. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Tafenoquine Market Value (USD Million) By Region

Table 74: Global Tafenoquine Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Type

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Type

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Type

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Global Tafenoquine Market Volume (K) By Region

Table 91: Global Tafenoquine Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Type

Table 94: North America Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Type

Table 97: Europe Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Type

Table 103: South America Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current Tafenoquine market size?

The global Tafenoquine market size is valued at USD 78 million in 2023, driven by rising demand for anti-relapse malaria therapy and expanding access in malaria-endemic regions.

2. What is the forecasted growth of the Tafenoquine market?

Analysts project the Tafenoquine market to grow at a 9.2% CAGR through 2030, reaching USD 145 million, fueled by increased travel-related prophylaxis and WHO endorsement.

3. What are the key drivers behind Tafenoquine adoption?

Key drivers include single-dose radical cure convenience, growing multidrug resistance to primaquine, government malaria elimination programs, and rising global travel to endemic regions.

4. What challenges restrain the Tafenoquine market?

High cost per treatment course, G6PD testing requirement, limited awareness among rural prescribers, and stringent storage conditions create adoption barriers and slow volume uptake.

5. Which regions lead the Tafenoquine market?

Asia-Pacific dominates with 52% share thanks to India, Indonesia, and PNG procurement; Latin America follows at 23%, while Africa accelerates adoption via pilot elimination campaigns.

6. Who are the top companies in the Tafenoquine space?

GlaxoSmithKline and Medicines for Malaria Venture co-developed the product; leading distributors include Cipla, F. Hoffmann-La Roche, and local tender winners in endemic countries.

7. What future opportunities exist for Tafenoquine?

Future outlook includes pediatric indication expansion, combination therapy development, chemoprotection in travelers, and entry into private-sector markets of high-burden countries.

8. How is technology impacting the Tafenoquine market?

Point-of-care G6PD biosensors shorten test turnaround, drone-based supply chains reduce last-mile gaps, and digital adherence apps improve compliance, collectively widening Tafenoquine accessibility.

9. What is the regulatory landscape for Tafenoquine?

Tafenoquine is FDA-approved for 16+ ages, EMA-authorized under risk-management programs, and pre-qualified by WHO; ongoing label extensions focus on pediatric waiver and pregnancy safety.

Contact for Full Report

Loading report content...

Tafenoquine Expansion Opportunities & Forecast Analysis 2033

Market Snapshot

Tafenoquine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Tafenoquine Segmentation

Tafenoquine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Tafenoquine market size?

2. What is the forecasted growth of the Tafenoquine market?

3. What are the key drivers behind Tafenoquine adoption?

4. What challenges restrain the Tafenoquine market?

5. Which regions lead the Tafenoquine market?

6. Who are the top companies in the Tafenoquine space?

7. What future opportunities exist for Tafenoquine?

8. How is technology impacting the Tafenoquine market?

9. What is the regulatory landscape for Tafenoquine?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Tafenoquine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Tafenoquine Segmentation

Tafenoquine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Tafenoquine market size?

2. What is the forecasted growth of the Tafenoquine market?

3. What are the key drivers behind Tafenoquine adoption?

4. What challenges restrain the Tafenoquine market?

5. Which regions lead the Tafenoquine market?

6. Who are the top companies in the Tafenoquine space?

7. What future opportunities exist for Tafenoquine?

8. How is technology impacting the Tafenoquine market?

9. What is the regulatory landscape for Tafenoquine?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation